Global Hepatitis C Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: precision business insights
Veröffentlicht am: 08.02.2018 06:35
Rubrik: Logistik & Verkehr

(Presseportal openBroadcast) - Hepatitis C treatment market: Hepatitis C is an infectious disease caused by Hepatitis C virus (HCV) and affects primarily the liver. Hepatitis C is commonly caused by blood to blood contacts such as intravenous drug use, unsterilized equipment, blood transfusions, and sexual intercourse. Hepatitis C may also cause from mother to fetus during birth. People with alcoholism and HIV infection of any age group are at increased risk. Currently, there is no vaccine available to treat hepatitis C conditions. However, various drugs such as protease inhibitors, HCV polymerase inhibitors, and HCV NS5A inhibitors are commonly used to treat Hepatitis C. Early stage of infection typically has no symptoms. The critical stage of infection may display symptoms such as fever, dark urine, abdominal pain, and yellow-tinged skin occurrence. The severity in hepatitis C may lead to liver cirrhosis, liver cancer, liver failure, and sometimes also causes the dilated blood vessels in the oesophagus and stomach. Hepatitis C can be prevented by using sterilized equipment, screening of blood donors, avoiding multiple sexual partners, and avoiding sharing of injections and razors.
Global Market Outline: Hepatitis C Treatment Market
The global market for Hepatitis C treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis C infection. Rising awareness regarding Hepatitis C treatment, increase in healthcare expenditure, and government initiatives and various NGO’s creating awareness regarding the Hepatitis C treatment is expected to fuel the market growth over the forecast period. In addition, rise in the funding in research and development activities for Hepatitis C treatment and strong pipeline products might boost the global Hepatitis C treatment market over the forecast period. However, lack of antibiotics in the market, high cost of medications, and lack of hepatitis C infection awareness in poor countries might hamper the growth of global Hepatitis C treatment market over the forecast period.

A sample of this report is available upon request @

Hepatitis C treatment market segmented on the basis of drug class, route of administration, and distribution channel

Based on drug class, the hepatitis C treatment market has been segmented into the following:
• Polymerase Inhibitors
• NS5A Inhibitors
• Interferons
• HCV protease inhibitors
• Combination Therapy

Based on route of administration, the hepatitis C treatment market has been segmented into the following:
• Oral
• Parenteral

Based on distribution channel, the hepatitis C treatment market has been segmented into the following:
• Retail Pharmacies
• Hospital Pharmacies
• Others

To view TOC of this report is available upon request @

Increase in prevalence of hepatitis C infection and liver cirrhosis expected to fuel the growth of Hepatitis C treatment market. According to the World Health Organization (WHO), globally there are 80 Mn people suffers from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market. For instance, in July 2011, Merck MSD, inked an agreement with Roche for the marketing approvals of Victreli (Boceprevir) triple combination therapy with peginterferon alfa and ribavirin (peg/riba). In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm (Telaprevir) tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission (EC) granted marketing authorization for Gilead’s Sovaldi (Sofosbuvir) to treat chronic hepatitis C infection.

Need more information about this report @

Geographically, the hepatitis C treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global hepatitis C treatment market followed by Europe and Asia-Pacific. Increase in prevalence of hepatitis C infection (according to Centres for Disease Prevention and Control (CDC), approximately 2.7-3.9 Mn people in the United States are chronically infected with hepatitis C Virus), rise in the awareness among the key stakeholders towards the use of novel products and technologies to treat the hepatitis C, and increase in research and development activities are the key factors bolster the hepatitis C treatment market in North America region. Europe holds a key share in hepatitis C treatment market owing to increase in prevalence of Hepatitis C infection (according to European centre for Disease Prevention and Control approximately 5.9 Mn people are suffering from HCV infection), rise in the geriatric population, change in the lifestyle, people involving in the unprotected sexual intercourse, and increase in the research and development activities might boost the hepatitis C treatment market in Europe region. Asia-Pacific hepatitis C treatment market growth is attributed to increase in the prevalence of hepatitis C infection, rise in the population in Asia-Pacific region, and increase in the healthcare infrastructure. The Middle East & Africa region has high prevalence of HCV infection majorly in Egypt that is approximately 8434 prevalent cases per 100,000 people.

Some of the players in Hepatitis C treatment market are GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), F. Hoffmann- La Roche Ltd. (Switzerland), Merck & Co, Inc. (U.S), Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Inc. (U.S.), and Kadmon Holdings, Inc. (U.S.) to name a few.

Get access to full summary @



Toll Free (US): +1-866-598-1553
Website @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.